Zanubrutinib vs Ibrutinib in Relapsed or Refractory CLL
In an interim analysis of the phase III ALPINE trial reported in the Journal of Clinical Oncology, Peter Hillmen, MBChB, PhD, and colleagues found that zanubrutinib...
Study Examines Coping Strategies Used by Caregivers of Patients Undergoing Stem Cell Transplants
November is Caregiver Awareness Month, and timely findings from a study published by Amonoo et al in the journal Blood Advances suggested that, among caregivers...
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors
As reported in JAMA Oncology by Schram et al, the phase IIb tumor-agnostic JAVELIN BRCA/ATM trial has shown that the combination of avelumab and talazoparib...
Patients Who Are HIV-Positive and Have Cancer May Have Accelerated Epigenetic Aging
Patients with cancer who are living with the human immunodeficiency virus (HIV) infection had an increased epigenetic age compared with...
ASCO Coronavirus Resources
As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...
Bruce Cheson: Death and Clinical Trials in the Plague Years
Daniel Vorobiof and Irad Deutsch: The Value of Managing Aggregated Data From Patients’ Online Communities
Kathleen Moore: ARIEL4 Confirms Rucaparib’s Efficacy in Recurrent, BRCA-Mutated Ovarian Cancer: Does It Tell Us Anything New?
Sergey Kozhukhov, and colleagues on Cancer and War in Ukraine: How the World Can Help Win This Battle
Ronald DePinho: Basic Research Enterprise Needs Adequate Funding to Foster Treatment Innovation
Sponsored Content
Sponsored by Pharmacyclics
Evolving Role of BTK Inhibitors in the Front-Line Treatment of Chronic Lymphocytic Leukemia
OlympiA: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early-Stage HER2-Negative Breast Cancer
One year of adjuvant therapy with the PARP inhibitor olaparib extended disease-free survival in patients with high-risk, early-stage, HER2-negative breast cancer with BRCA1/2 germline mutations, according to a prespecified interim analysis of the phase III OlympiA trial presented by Andrew Tutt, MB ...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Are There Differences in the Prevalence of Germline Pathogenic Variants in Susceptibility Genes in Black vs White Women With Breast Cancer?
In a population-based study reported in JAMA Oncology, Susan M. Domchek, MD, and colleagues found “no clinically meaningful differences” in the prevalence of germline pathogenic variants in 12 established breast cancer susceptibility genes between Black and non-Hispanic White women with breast...
Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Who Received Chest Radiation
In an analysis from the Childhood Cancer Survivor Study (CCSS) and the Dutch Hodgkin Late Effects and LATER cohorts reported in the Journal of Clinical Oncology, Moskowitz et al developed a model for predicting the risk of breast cancer among childhood cancer survivors treated with chest...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
KEYNOTE-361: First-Line Pembrolizumab With or Without Chemotherapy vs Chemotherapy Alone in Advanced Urothelial Carcinoma
As reported in The Lancet Oncology by Thomas Powles, MD, PhD, and colleagues, the phase III KEYNOTE-361 trial has shown no significant improvement in progression-free or overall survival with first-line pembrolizumab plus platinum-based chemotherapy vs chemotherapy alone in patients with advanced...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
